<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676868</url>
  </required_header>
  <id_info>
    <org_study_id>JDS_2018_6</org_study_id>
    <nct_id>NCT03676868</nct_id>
  </id_info>
  <brief_title>Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations</brief_title>
  <acronym>BioMAV</acronym>
  <official_title>Biology of Cerebral Arteriovenous Malformations : Study of the Link Between Blood Biomarkers and the Haemorrhagic Prognosis of Cerebral Arteriovenous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cerebral arteriovenous malformations correspond to the formation of an entanglement of
      morphologically abnormal vessels called nidus, which shunt the blood circulation directly
      from the arterial circulation to the venous circulation.

      The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke.

      The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous
      malformations would come from peri-nidal micro-vessels, in connection with infiltration of
      leucocytes and / or defective maintenance of microvascular integrity by platelets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">October 2034</completion_date>
  <primary_completion_date type="Anticipated">October 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic</measure>
    <time_frame>6 months</time_frame>
    <description>associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associaton between dosage of platelet and the arteriovenous malformation pronostic</measure>
    <time_frame>6 months</time_frame>
    <description>Dosage of platelet in blood samples and correlation with clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic</measure>
    <time_frame>6 months</time_frame>
    <description>Dosage of neutrophilic in blood samples and correlation with clinical outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic</measure>
    <time_frame>6 months</time_frame>
    <description>Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cerebral Arteriovenous Malformations</condition>
  <condition>Ruptured or Unruptured Cerebral Arteriovenous Malformations</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a cerebral arterioveinus malformation for which an intervention (endovascular
        treatment or surgery) or only clinical monitoring is planned
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Patient with a cerebral AVM for which an intervention (endovascular treatment or
             surgery) or only clinical monitoring

          -  Express consent to participate in the study

        And

          -  children

          -  Free informed and express consent of both holders of the minor patient's parental
             authority, or, by way of derogation and only if the other holder of parental authority
             cannot give his or her consent within a time limit compatible with the methodological
             requirements specific to the conduct of the research with regard to its purposes, of
             one of the two holders of parental authority

        Exclusion Criteria:

          -  Patient benefiting from a legal protection measure

          -  Pregnant or breast feeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Laurence SALOMON</last_name>
    <phone>01 48 63 64 31</phone>
    <phone_ext>+33</phone_ext>
    <email>l.salomon@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Philippe DESILLES</last_name>
    <email>jp.desilles@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Rotschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Jean-Philippe DESILLES</last_name>
      <email>jpdesilles@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

